The molecular mechanisms and metabolic pathways whereby the citrus flavonoid, naringenin, reduces dyslipidemia and improves glucose tolerance were investigated in C57BL6/J wild-type mice and fibroblast growth factor 21 (FGF21) null (Fgf21 Ϫ/Ϫ ) mice. FGF21 regulates energy homeostasis and the metabolic adaptation to fasting. One avenue of this regulation is through induction of peroxisome proliferator-activated receptor-␥ coactivator-1␣ (Pgc1a), a regulator of hepatic fatty acid oxidation and ketogenesis. Because naringenin is a potent activator of hepatic FA oxidation, we hypothesized that induction of FGF21 might be an integral part of naringenin's mechanism of action. Furthermore, we predicted that FGF21 deficiency would potentiate high-fat diet (HFD)-induced metabolic dysregulation and compromise metabolic protection by naringenin. The absence of FGF21 exacerbated the response to a HFD. Interestingly, naringenin supplementation to the HFD robustly prevented obesity in both genotypes. Gene expression analysis suggested that naringenin was not primarily targeting fatty acid metabolism in white adipose tissue. Naringenin corrected hepatic triglyceride concentrations and normalized hepatic expression of Pgc1a, Cpt1a, and Srebf1c in both wild-type and Fgf21 Ϫ/Ϫ mice. HFD-fed Fgf21 Ϫ/Ϫ mice displayed greater muscle triglyceride deposition, hyperinsulinemia, and impaired glucose tolerance as compared with wildtype mice, confirming the role of FGF21 in insulin sensitivity; however, naringenin supplementation improved these metabolic parameters in both genotypes. We conclude that FGF21 deficiency exacerbates HFD-induced obesity, hepatic steatosis, and insulin resistance. Furthermore, FGF21 is not required for naringenin to protect mice from HFD-induced metabolic dysregulation. Collectively these studies support the concept that naringenin has potent lipid-lowering effects and may act as an insulin sensitizer in vivo. A berrant glucose and lipid homeostasis define a constellation of metabolic abnormalities including obesity, dyslipidemia, insulin resistance, and type 2 diabetes, suggesting that restoration of energy homeostasis is critical for therapeutic intervention (1-4). Previously we demonstrated that the citrus flavonoid, naringenin, is a
and the metabolic adaptation to fasting. One avenue of this regulation is through induction of peroxisome proliferator-activated receptor-␥ coactivator-1␣ (Pgc1a), a regulator of hepatic fatty acid oxidation and ketogenesis. Because naringenin is a potent activator of hepatic FA oxidation, we hypothesized that induction of FGF21 might be an integral part of naringenin's mechanism of action. Furthermore, we predicted that FGF21 deficiency would potentiate high-fat diet (HFD)-induced metabolic dysregulation and compromise metabolic protection by naringenin. The absence of FGF21 exacerbated the response to a HFD. Interestingly, naringenin supplementation to the HFD robustly prevented obesity in both genotypes. Gene expression analysis suggested that naringenin was not primarily targeting fatty acid metabolism in white adipose tissue. Naringenin corrected hepatic triglyceride concentrations and normalized hepatic expression of Pgc1a, Cpt1a, and Srebf1c in both wild-type and Fgf21 Ϫ/Ϫ mice. HFD-fed Fgf21 Ϫ/Ϫ mice displayed greater muscle triglyceride deposition, hyperinsulinemia, and impaired glucose tolerance as compared with wildtype mice, confirming the role of FGF21 in insulin sensitivity; however, naringenin supplementation improved these metabolic parameters in both genotypes. We conclude that FGF21 deficiency exacerbates HFD-induced obesity, hepatic steatosis, and insulin resistance. Furthermore, FGF21 is not required for naringenin to protect mice from HFD-induced metabolic dysregulation. Collectively these studies support the concept that naringenin has potent lipid-lowering effects and may act as an insulin sensitizer in vivo. A berrant glucose and lipid homeostasis define a constellation of metabolic abnormalities including obesity, dyslipidemia, insulin resistance, and type 2 diabetes, suggesting that restoration of energy homeostasis is critical for therapeutic intervention (1) (2) (3) (4) . Previously we demonstrated that the citrus flavonoid, naringenin, is a potent inhibitor of apolipoprotein B100 secretion from cultured hepatoma cells (5) (6) (7) (8) (9) (10) . We extended these studies to a well-established model of dyslipidemia and atherosclerosis, the high-fat diet (HFD) fed Ldlr Ϫ/Ϫ mouse, in which the administration of naringenin lowered very lowdensity lipoprotein production, corrected dyslipidemia, improved glucose and insulin tolerance, reduced hepatic lipid accumulation, and attenuated atherosclerosis (11) (12) (13) (14) . Naringenin treatment induced hepatic fatty acid oxidation, which reduced lipid availability, especially triglycerides (TGs), for the assembly and secretion of apolipoprotein B-containing lipoproteins, leading to reduced hepatic lipid accumulation and improved dyslipidemia (12) . Interestingly, unlike other polyphenols, naringenin did not stimulate fatty acid oxidation in skeletal muscle; instead naringenin reduced lipid accumulation and promoted glucose uptake (12) . These data suggest that naringenin may not act directly in muscle and reduced muscle lipid and improved glucose use is due to reduced lipoprotein uptake, a consequence of decreased very lowdensity lipoprotein secretion as well as reduced de novo lipogenesis, secondary to normalization of hyperinsulinemia. Additionally, naringenin prevents diet-induced weight gain and adiposity by increasing whole-body energy expenditure (12) . Other polyphenolic compounds prevent diet-induced adipose tissue accumulation through a variety of mechanisms including inhibition of preadipocyte differentiation, stimulating lipolysis, and increasing mitochondrial function (15) . However, the molecular mechanisms by which naringenin stimulates hepatic ␤-oxidation and prevents HFD-induced adipose tissue accumulation remain to be fully elucidated. Previously we identified that naringenin induces hepatic fatty acid oxidation, which was coupled to the induction of peroxisome proliferator-activated receptor (PPAR)-␥ coactivator-1␣ (Pgc1a) as well as the PPAR␣-target genes, carnitine palmitoyltransferase-1␣ (Cpt1a) and acylCoA oxidase 1 (Acox1), which code for rate-limiting enzymes in mitochondrial and peroxisomal fatty acid oxidation, respectively (11, 12) . However, naringenin is not a direct PPAR␣ activator (12) . Recently we reported that naringenin robustly increases hepatic Fgf21 expression in mice on high-fat-high-cholesterol or low-fat-highcholesterol diets, suggesting it may be essential in mediating naringenin's metabolic effects (11) .
Fibroblast growth factor (FGF) 21 is induced by fasting, or more specifically reduced intake of protein, and is regulated, in part, by the transcription factor PPAR␣ (16 -19) . FGF21 is predominantly derived from the liver and signals through a complex including ␤-Klotho, which is selectively expressed in liver, adipose, and pancreas, and one of four tyrosine kinase FGF receptors (FGFR1c, FGFR 2c, FGFR 3c, and FGFR 4) (20 -25) . However, ␤-Klotho is not required for FGF21 signaling in adipose tissue (26) . FGF21 stimulates hepatic expression of PPAR␥ coactivator-1␣ (Pgc1a) (18, (27) (28) (29) , which regulates genes involved in ketogenesis and hepatic fatty acid (FA) oxidation including Cpt1a. Hepatoma cells transfected with an FGF21 construct demonstrated reduced TG content and lower levels of the nuclear form of sterol response element binding protein 1c (SREBP-1c) (30) , suggesting that FGF21 may reduce hepatic lipogenesis. The importance of FGF21 in regulating energy and lipid metabolism in vivo has been demonstrated in HFD-fed C57BL/6 mice, whereby injection of FGF21 improved hyperinsulinemia, improved insulin sensitivity, decreased hepatic expression of Srebf1c, reduced FA synthesis, attenuated hepatic steatosis, and increased energy expenditure (31) (32) (33) , results very similar to the response we observed in naringenintreated, HFD-fed mice (11, 12) . Furthermore, transgenic mice overexpressing hepatic FGF21 are lean, protected from HFD-induced insulin resistance, and exhibit an extended lifespan (34, 35) .
In this study, we tested whether naringenin action requires FGF21 for its metabolic effects on the regulation of white adipose tissue (WAT) energy homeostasis, hepatic lipid metabolism, and whole-body glucose homeostasis. We used Fgf21 Ϫ/Ϫ mice, which the current studies confirm as unique model of diet-induced obesity and metabolic dysfunction, in which the absence of FGF21 significantly enhanced the response to a HFD. Naringenin potently reduced lipid accumulation in all adipose tissue depots, the liver, and muscle independent of FGF21. For the first time, we evaluated naringenin's effect on the expression of genes involved in lipid homeostasis in WAT, and we conclude that the ability of naringenin to protect from HFD-induced metabolic dysregulation is independent of FGF21, and the primary site of action is not lipid metabolism in WAT. Collectively these findings add to the growing body of evidence that naringenin has marked lipid-lowering potential and demonstrate that it can normalize glucose tolerance and insulin sensitivity and prevent obesity, independent of FGF21. The ability of naringenin to modulate metabolic pathways linked to the metabolic syndrome suggests citrus flavonoids represent valuable tools in the search for regulators of insulin signaling, lipid homeostasis, and energy balance. (12) . Male Lep ob/ob mice (aged 6 wk) were fed a low-fat semisynthetic diet (Harlan Teklad; AIN-73A) Ϯ3% naringenin for 4 weeks (n ϭ 8/group). Food intake and body weight were measured three times per week. Caloric intake was calculated as described previously (11) . Mice were fasted for 4 hours prior to metabolic studies and being killed. Experiments were approved by the Animal Care and Use Subcommittee at the University of Western Ontario (protocol number 2008 -071).
Materials and Methods

Animals and diets
Plasma and tissue analyses
Mice were euthanized by CO 2 inhalation, and cardiac puncture was conducted to collect blood, which was stored at Ϫ20°C. Plasma insulin (ALPCO Diagnostics), FGF21 (EMD Millipore), FGF15 (Uscn Life Science Inc), leptin (Crystal Chem Inc), total adiponectin (Biovendor Inc), TNF␣ (eBioscience) and IGF-1 (R&D Systems) were determined by a mouse-specific ELISA. Plasma triglycerides (Roche Diagnostics) and plasma free fatty acids (FFAs) (Wako Chemicals) were measured enzymatically (12, 13, 38) . Liver and quadriceps were removed, snap frozen in liquid nitrogen, and stored at Ϫ80°C. Liver and muscle lipids were extracted and analyzed as described previously (12, 13, 38) .
Glucose and insulin tolerance tests
For glucose tolerance tests (GTTs), mice were fasted for 4 hours (Fgf21 Ϫ/Ϫ and C57BL/6 mice) or 6 hours (Lep ob/ob mice) and administered by gavage a 20% D-glucose solution in 0.9% NaCl (1 g/kg body weight). For insulin tolerance tests (ITT), nonfasted mice were injected ip with 0.6 IU/kg Novolin ge Toronto (Novo Nordisk). GTTs and ITTs were performed as described previously (12, 13, 38) .
Gene expression
Tissue mRNA levels were determined using a two-step quantitative real time-PCR protocol on an ABI Prism (model 7900 HT) sequence detection system (Applied Biosystems) according to the manufacturer's instructions. Primer probe sets were manufactured by Taqman Assays-on-Demand (Applied Biosystems) with the exception of Srebf1c, which was designed from the Mus musculus Srebf1 sequence (Genbank accession number AL669954), as described previously (12) . The 2(-Delta Delta threshold Cycle) method was used to estimate specific mRNA concentrations, and each gene was normalized to ␤-actin (Actb) or Gapdh expression.
Tissue sectioning and histology
WAT was fixed in 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. All photomicrographs were generated on an Olympus BX50 microscope with a QImaging Retiga EXi FAST camera (QImaging). Adipocyte diameter was calculated using Northern Eclipse 7.0 software on ϫ20 magnification photomicrographs (11) .
Microcomputed tomography (micro-CT) imaging
Male C57BL/6 and Fgf21 Ϫ/Ϫ mice were imaged after 8 weeks on a diet (n ϭ 4 -6/group). Whole-body composition analysis was conducted by micro-CT imaging using a Locus Ultra micro-CT scanner (GE Healthcare) (39) . Nonfasted mice were anesthetized with 1.5% isoflurane in O 2 . A calibrating phantom, comprising air and water, was scanned concurrently to ensure images were reconstructed equivalently. The scan protocol consisted of an x-ray tube voltage of 80 kVp and a current of 55.0 mA. In a scan time of 16 seconds, 1000 views were acquired in one continuous rotation. Images were reconstructed to an isotropic voxel size of 150 m 3 . Using the image values of water and air, data were calibrated into CT number, expressed in Hounsfield Units. The analysis was conducted using MicroView software version 2.2 (GE Healthcare). Total adipose tissue volume was calculated by selecting all voxels with values within a window of Ϫ225 to Ϫ60 Hounsfield Units and then divided into sc and visceral depots. Subcutaneous and visceral adipose tissue depots were differentiated using the muscular abdominal wall, which is readily identified because of its higher density (40) . The sc and visceral adipose depots were outlined manually and the volume of each region was calculated by MicroView as the number of voxels falling within the threshold window multiplied by the voxel volume (150 m 3 ). Adipose tissue was highlighted in red.
Statistical Analysis
Data are presented as the mean Ϯ SEM. An ANOVA was conducted to test the interaction between diet and genotype, followed by a post hoc Tukey test. Within a genotype, a one-way ANOVA was performed followed by a post hoc Tukey test. Different upper-case letters indicate statistical significance among wild-type (WT) mice (P Ͻ .05). Different lower-case letters indicate statistical significance among Fgf21 Ϫ/Ϫ mice (P Ͻ .05). An asterisk indicates statistical significance between genotypes (WT vs Fgf21 Ϫ/Ϫ ) fed the same diet, determined by a Student's unpaired t test (P Ͻ .05). Statistical analysis was performed using Sigma Plot version 14.0.
Results
Enhanced weight gain in HFD-fed Fgf21
؊/؊ mice is prevented by naringenin Previous studies determined that hepatic Fgf21 mRNA in Ldlr Ϫ/Ϫ animals that had been fed a HFD containing naringenin for 4 weeks was 3-fold higher than in mice fed the HFD alone (Supplemental Figure 1A) . Naringenin supplementation also increased fasting plasma FGF21 concentrations 2-fold compared with mice fed the HFD alone (Supplemental Figure 1B) . To further evaluate the requirement of FGF21 in the flavonoid-mediated reduction in metabolic abnormalities, we fed both WT and mice tended to be heavier than WT mice, a trend that persisted in naringenin-fed mice. No significant differences in caloric intake were observed among any of the groups (Supplemental Figure 2B ). In Fgf21 Ϫ/Ϫ mice, immunodetectable FGF21 in plasma was below the lowest assay standard, and hepatic Fgf21 mRNA was undetectable in all dietary groups (data not shown). Whole-body micro-CT imaging revealed that in chow-fed WT mice, the volume of adipose tissue (red) in the sc depot was approximately 2-fold higher than in the visceral depot ( Figure 1 ). A similar relationship was observed in chow-fed Fgf21
mice, although adipose tissue volume in each depot was significantly elevated (2-to 3-fold) relative to WT mice ( Figure 1 , A-C). In both genotypes, the HFD increased adipose tissue volume in the visceral depot to a greater extent than the sc depot (7.3-fold vs 3.9-fold, respectively) ( increased adiposity in HFD-fed Fgf21 Ϫ/Ϫ mice ( Figure   2D ). In both genotypes, naringenin markedly reduced circulating leptin levels, although levels remained higher in Fgf21 Ϫ/Ϫ mice. Plasma adiponectin was increased approximately 25% in HFD-fed WT mice but not in HFD-fed Fgf21 Ϫ/Ϫ mice ( Figure 2E ), consistent with increased adiposity in the latter mice and with a report that FGF21 is a potent regulator of adiponectin secretion (42) . Naringenin induced normal plasma levels of adiponectin in HFD-fed mice, independent of genotype ( Figure 2E ). Enhanced ectopic lipid accumulation promotes systemic inflammation due to secretion of proinflammatory cytokines from WAT (43) . Therefore, the significant increase in plasma TNF␣ in HFD-fed Fgf21 Ϫ/Ϫ mice is consistent with increased adiposity ( Figure 2F ). Naringenin treatment suppressed plasma TNF␣, independent of genotype ( Figure 2F ). Plasma levels of the related FGF15 or IGF-1 were unaffected by diet or genotype (data not shown). 
Gene profiling of WAT reveals naringenin does not significantly target genes regulating lipid metabolism
The increased adiposity in HFD-fed Fgf21 Ϫ/Ϫ mice and its prevention by naringenin led us to explore the expression of genes that regulate lipid metabolism in WAT. To evaluate fatty acid oxidation, we examined Pgc1a and Cpt1a. In both genotypes, Pgc1a expression was similar; its expression was attenuated approximately 65% by the HFD, whereas expression was completely restored by naringenin ( Figure 3A ). Cpt1a expression was also similar between genotypes, the HFD reduced Cpt1a expression to a similar extent in WT and Fgf21 Ϫ/Ϫ mice, and naringenin had no further effect ( Figure 3B ). In addition to its regulation of oxidative metabolism, Pgc1␣ regulates thermogenesis (44) . Concomitant with decreased Pgc1a in HFDfed WT mice compared with chow-fed WT mice, uncoupling protein 1 (Ucp1) expression decreased approximately 70%, whereas naringenin increased Ucp1 mRNA 3-fold. In contrast, WAT Ucp1 mRNA in chowfed Fgf21 Ϫ/Ϫ mice was not different from WT, and neither the HFD nor naringenin affected its expression ( Figure  3C ). Because both adipose TG lipase (Pnpla2) and hormone-sensitive lipase (Lipe) can liberate FAs, which may indirectly activate a PPAR␣ transcription program, we assessed their mRNA abundance (45, 46) . Lipe was lower in HFD-fed Fgf21 Ϫ/Ϫ mice compared with HFD-fed WT mice, consistent with increased adiposity in HFD-fed Fgf21 Ϫ/Ϫ mice. Naringenin treatment increased Pnpla2
and Lipe expression in both genotypes, suggesting that their up-regulation was not dependent on FGF21 ( Figure  3 , D and E). The nuclear hormone receptor Ppara was suppressed in HFD-fed Fgf21 Ϫ/Ϫ mice compared with HFD-fed WT mice, consistent with increased adiposity in HFD-fed Fgf21 Ϫ/Ϫ mice ( Figure 3F ). However, levels of Ppara mRNA in naringenin-treated mice were not different between genotypes, nor were they different from HFDfed mice, suggesting that differences in Ppara expression do not play a role in the decreased adiposity induced by naringenin.
To provide insight into the effect of naringenin on lipogenesis, we evaluated WAT expression patterns of carbohydrate-responsive element-binding protein (Chrebp) and Pparg. Levels of Chrebp were modestly affected by diet ( Figure 3G ). However, there were no differences between genotypes and thus did not explain the increased adiposity or the naringenin-induced attenuation of adipose tissue in Fgf21 Ϫ/Ϫ mice. Lower levels of Pparg mRNA abundance were observed in HFD-fed Fgf21
mice compared with HFD-fed WT mice, consistent with increased adiposity observed in Fgf21 Ϫ/Ϫ mice; however, no differences were observed with naringenin treatment ( Figure 3H ). The WAT leptin receptor (Lepr) expression was significantly decreased (Ͼ60%) by HFD feeding and was partially restored by naringenin, independent of genotype ( Figure 2I ). In both genotypes, the HFD decreased WAT Klb (␤-Klotho) (Ϫ45%) and naringenin did not further affect its expression. Fgfr1 and 2 mRNA were unchanged in WT mice. In HFD-fed Fgf21 Ϫ/Ϫ mice, Fgfr2 expression was lower compared with HFD-fed WT mice, and both Fgfr1 and Fgfr2 were increased by the addition of naringenin (Supplemental Figure 3) .
Naringenin prevents dyslipidemia and improves glucose metabolism in Lep ob/ob mice independent of changes in weight or adiposity
In both WT and Fgf21 Ϫ/Ϫ mouse models, naringenin significantly reduced diet-induced weight gain. To determine whether prevention of weight gain or obesity was a primary requirement for the metabolic protection observed in naringenin-treated animals, we performed similar studies in Lep ob/ob mice, a genetic model characterized by severe obesity and insulin resistance. Male Lep ob/ob mice were fed a low-fat semisynthetic diet Ϯ 3% naringenin for 4 weeks. As observed previously, the Lep ob/ob mice were hyperphagic compared with C57BL/6 controls (47). However, food intake was not affected by the addition of naringenin (data not shown). In this model, body weight and the adiposity index were unaffected by naringenin treatment (Figure 4, A and B) . The Lep ob/ob mice have steatotic livers, even in the absence of high-fat feeding. Liver TG was 10-fold greater than for C57BL/6 mice fed the same diet (data not shown). Naringenin significantly reduced liver TG by 25%, which coincided with a decrease in plasma TG concentrations of 75% (Figure 4 , C and D). Hyperinsulinemia and modest hyperglycemia were observed in the Lep ob/ob mice, which were significantly reduced with naringenin by 50% and 25%, respectively ( Figure 4, E and F) . Lep ob/ob mice demonstrated significant impairment in glucose tolerance. Naringenin supplementation enhanced glucose tolerance as indicated by a significant reduction in the GTT area under the curve (AUC) (Figure 4, G and H) . Therefore, reduced body weight and decreased adiposity were not the primary mechanisms for the naringenin-induced improvements in metabolic indices in WT and Fgf21 Ϫ/Ϫ mice.
Ectopic lipid accumulation in HFD-fed Fgf21
؊/؊ mice is prevented by naringenin In our previous studies, naringenin significantly improved hepatic lipid and lipoprotein metabolism (11, 12) . Therefore, we evaluated the requirement of FGF21 in mediating these effects. In chow-fed WT and Fgf21 Ϫ/Ϫ mice, no differences were observed in hepatic TG mass; how-ever, the absence of FGF21 exacerbated HFD-diet induced hepatic TG accumulation (by 3-fold) compared with HFD-fed WT mice ( Figure 5A ). Naringenin completely prevented the increase in hepatic TG (Ͼ96%) such that concentrations in treated mice were not different between genotypes. The absolute reduction in hepatic lipids in- Ϫ/Ϫ mice fed a chow diet, a HFD, or a HFD supplemented with 3% naringenin (Nar) for 16 weeks (n ϭ 6 -7/ group). Values are the mean Ϯ SEM (n ϭ 6 -7/group) and are normalized to Actb (␤-actin). Different upper-case letters indicate statistical significance among WT animals (P Ͻ .05). Different lower-case letters indicate statistical significance among Fgf21 Ϫ/Ϫ mice (P Ͻ .05). *, Statistical significance between genotypes (WT vs Fgf21 Ϫ/Ϫ ) fed the same diet (P Ͻ .05). duced by naringenin was significantly greater in HFD-fed Fgf21 Ϫ/Ϫ mice compared with HFD-fed WT mice ( Figure   5A ). Intramyocellular lipids are associated with insulin resistance in vivo (12) . The HFD significantly increased TG accumulation in quadriceps muscle of WT mice 1.6-fold, whereas quadriceps TG in Fgf21 Ϫ/Ϫ mice fed the HFD markedly increased 3.2-fold, compared with chowfed mice ( Figure 5B ). Although muscle TG was reduced greater than 90% by naringenin in both genotypes, levels remained significantly higher in Fgf21 Ϫ/Ϫ mice compared with WT mice ( Figure 5B ). The HFD did not increase plasma TGs in either genotype ( Figure 5C ). Naringenin reduced plasma TGs in HFD-fed WT mice (Ϫ30%). In HFD-fed Fgf21 Ϫ/Ϫ mice, naringenin had no effect on plasma TGs, suggesting that the decrease in tissue TGs was unrelated to plasma TG levels ( Figure 5 , A-C). Plasma FFA concentrations were unchanged by any dietary group or genotype ( Figure 5D ). . Naringenin-treatment of Lep ob/ob mice improves glucose tolerance, dyslipidemia, and hepatic TG accumulation independent of any effect on body weight and adiposity. Male Lep ob/ob mice were fed a low-fat semisynthetic diet Ϯ naringenin (3%) for 4 weeks (n ϭ 8/group). Body weight was measured biweekly (A). Adiposity Index was calculated as the weight of epididymal adipose stores/total body weight (B). Hepatic TG mass (C) and plasma TG concentrations (D) were determined in mice fasted for 6 hours. Plasma insulin (E) and blood glucose (F) were determined in mice after a 6-hour fast. A GTT was performed by gavage of 20% glucose (1 g/kg body weight) (G). The GTT AUC was calculated (H). Values are the mean Ϯ SEM (n ϭ 8/group). Different letters indicate statistical significance (P Ͻ .05).
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Naringenin reduces gene expression of hepatic lipogenic genes and up-regulates hepatic FA oxidation genes, independent of FGF21
To explore the HFD-induced increase in hepatic TGs and its prevention by naringenin in both genotypes, we evaluated the FA oxidation genes Pgc1a and Cpt1a. Expression of Pgc1a was attenuated in HFD-fed Fgf21 Ϫ/Ϫ mice to a greater extent (Ϫ58%) than in HFD-fed WT mice (Ϫ36%), compared with chow-fed controls ( Figure  6A ). Naringenin supplementation increased Pgc1a expression greater than 30%, in both genotypes. The HFD suppressed Cpt1a expression significantly (70%-80%) in both genotypes ( Figure 6B ). Naringenin supplementation increased Cpt1a mRNA to similar levels in both genotypes. Acox1 and Ppara mRNAs were unaffected by diet or genotype ( Figure 6, C and D) . The expression of genes involved in hepatic lipogenesis were also examined. Expression of sterol regulatory element binding factor 1c (Srebf1c) was significantly increased (ϳ2.5-fold) in both HFD-fed WT and Figure 6H ). Scd1 expression was normalized by naringenin in both genotypes. Pparg mRNA was unaffected by diet or genotype ( Figure 6I ). HFD feeding did not affect Lepr expression in either genotype. Naringenin significantly increased Lepr expression in HFD-fed WT mice (ϳ2-fold) but not in HFD-fed Fgf21 Ϫ/Ϫ mice ( Figure 6J ).
Hepatic expression of Klb and Fgfr1 were reduced by the HFD in Fgf21 Ϫ/Ϫ mice, and this was unaffected by naringenin addition. Fgfr2 was unaffected by genotype or by naringenin in HFD-fed mice (Supplemental Figure 4) .
Naringenin prevents hyperinsulinemia and improves glucose homeostasis in both HFD-fed WT and Fgf21 ؊/؊ mice
As recently reported in mice fed a HFD or a ketogenic diet, deletion of Fgf21 elevated plasma insulin (36, 48) . In the present study, the HFD increased fasting plasma insulin in Fgf21 Ϫ/Ϫ mice by 7.5-fold, which was significantly greater than the 4-fold increase observed for HFD-fed WT mice, as compared with chow-fed controls ( Figure 7A ).
This implies that HFD-fed Fgf21
Ϫ/Ϫ mice require significantly more insulin to maintain plasma glucose at levels similar to those in HFD-fed WT mice ( Figure 7B ). Naringenin supplementation to the HFD markedly attenuated Figure 6 . Gene expression profiling in liver of WT and Fgf21 Ϫ/Ϫ mice. mRNA abundance was measured in liver collected from male WT and Fgf21 Ϫ/Ϫ mice fed a chow diet, a HFD, or a HFD supplemented with 3% naringenin (Nar) for 16 weeks (n ϭ 6 -7/group). Data are given as mean Ϯ SEM (n ϭ 6 -7/group) and are normalized to Actb (␤-actin). Different upper-case letters indicate statistical significance among WT animals (P Ͻ .05). Different lower-case letters indicate statistical significance among Fgf21 Ϫ/Ϫ mice (P Ͻ .05). *, Statistical significance between genotypes (WT vs Fgf21 Ϫ/Ϫ fed the same diet (P Ͻ .05). 
Discussion
Obesity, dyslipidemia, and type 2 diabetes are an emerging epidemic poised to place significant strain on global health resources (49) . Increased visceral obesity has been linked to greater plasma concentrations of FFAs (50). However, due to its anatomical location, it has also been proposed that very few circulating FAs derived from visceral adipose tissue depots and released into the portal vein escape metabolism by the liver, thereby limiting direct contact with other tissues (51, 52) . In this context, maintaining hepatic insulin sensitivity and reducing hyperinsulinemia-mediated de novo lipogenesis and the hepatic overproduction of TG-rich lipoproteins may prevent lipid deposition within peripheral tissues. It has been proposed that accretion of lipid metabolites in muscle activates signaling cascades leading to insulin resistance (53) , which contributes to decreased glucose uptake and use (54) . Therefore, therapeutic interventions that reduce hyperinsulinemia and prevent the overproduction of apolipoprotein B100-containing lipoproteins have the potential to reduce ectopic lipid accumulation and prevent metabolic dysregulation in insulin-resistant states. Previously we described naringenin to have potent lipid lowering properties in Ldlr Ϫ/Ϫ mice, which was associated with a significant up-regulation of FGF21 (11).
FGF21 plays an important role in the regulation of glucose, lipid, and energy homeostasis and has therapeutic potential (34, 55) . To further elucidate the molecular mechanisms mediating naringenin's robust glucose and lipid lowering, we assessed the impact of FGF21 deficiency on the ability of naringenin to achieve metabolic protection. HFD-fed Fgf21 Ϫ/Ϫ mice accumulated significantly more adipose tissue compared with their WT counterparts. Conversely, naringenin markedly attenuated HFDinduced fat accumulation in both WT and Fgf21 Ϫ/Ϫ mice.
The HFD amplified hepatic steatosis in Fgf21 Ϫ/Ϫ mice, compared with WT animals. In contrast, naringenin completely normalized hepatic lipid accumulation, independent of genotype, through similar decreases in the hepatic expression of genes involved in lipogenesis and increases in the expression of those involved in FA oxidation. In Fgf21 Ϫ/Ϫ mice, the HFD intensified hyperinsulinemia and impaired glucose tolerance relative to HFD-fed WT mice. Naringenin normalized plasma insulin, restored glucose homeostasis, and improved insulin sensitivity, even in the absence of FGF21. Although a HFD amplifies the metabolic dysregulation in Fgf21 Ϫ/Ϫ mice, the ability of naringenin to attenuate adiposity, correct hepatic steatosis, and normalize glucose intolerance is independent of FGF21.
The most prominent phenotype in HFD-fed Fgf21 Ϫ/Ϫ mice was enhanced weight gain (170%) and adiposity in both visceral (200%) and sc (180%) fat depots, compared with HFD-fed WT controls, despite no difference in caloric consumption (36, 48) . A similar difference in phenotype was observed upon feeding Fgf21 Ϫ/Ϫ mice either a chow, ketogenic diet, or a HFD, although the adipose tissue increases were more modest (36, 41, 48) . However, a third strain of Fgf21 Ϫ/Ϫ mice fed a HFD were reported to be leaner as compared with WT mice (56) , and the reasons for this discrepancy are currently unknown (56) . In the present study, HFD-fed Fgf21 Ϫ/Ϫ mice demonstrated an increased size and number of lipid-rich adipocytes in epididymal fat compared to HFD-fed WT mice. Moreover, naringenin significantly attenuated adipose tissue accumulation and normalized adipocyte hypertrophy and hyperplasia. Consistent with increased adiposity in HFD-fed Fgf21 Ϫ/Ϫ mice was the almost 2-fold increase in plasma leptin compared with HFD-fed WT mice. However, naringenin significantly reduced circulating leptin levels, although the reduction was greater in WT than in Fgf21
mice. These data suggest that naringenin may enhance leptin sensitivity, thereby contributing to reduced fat mass. Hepatic expression of Lepr, known to be stimulated by FGF21 (27) , was significantly increased by naringenin in WT but not in Fgf21 Ϫ/Ϫ mice, suggesting that up-reg-ulation of Lepr is FGF21 dependent. The lack of a significant effect of naringenin on hepatic Lepr expression, together with higher plasma leptin, may contribute to the residual adiposity in naringenin-treated Fgf21 Ϫ/Ϫ mice.
The HFD-induced increase in plasma adiponectin in WT mice, but not in Fgf21 Ϫ/Ϫ mice, has been observed previously (42) . Although adiponectin is required for the metabolic improvements of exogenous FGF21 treatment (42, 57) , it is not clear from the present studies whether the normal plasma levels of adiponectin in naringenin-treated mice represent a direct effect of naringenin or are a consequence of normalized adipose tissue mass. Gene expression analysis in WAT provided limited insight into the mechanism of protection from diet-induced obesity conferred by naringenin. In WAT, exogenous FGF21 is known to induce Pgc1a mRNA and protein as well as potently induce Ucp1 expression (44) . The latter effect has been linked to the browning of WAT, increased energy expenditure, and reduced adipose tissue mass with FGF21 treatment (27, 31, 44) . The present study was conducted at 23°C and not at thermoneutrality, suggesting a small stimulus for the browning of WAT. However, the WAT pattern of Pgc1a mRNA suppression by HFD and its restoration by naringenin were similar in both genotypes, suggesting the naringenin effect on Pgc1a was FGF21 independent. In addition, in both WT and Fgf21 Ϫ/Ϫ mice, Cpt1a mRNA expression in WAT was suppressed by the HFD, and its expression was unaltered by naringenin. Another striking phenotype observed in HFD-fed Fgf21 Ϫ/Ϫ mice was the exacerbated hepatic lipid accumulation, demonstrating the importance of FGF21 in regulating the hepatic response to increased dietary fat. These data are consistent with Fgf21 Ϫ/Ϫ mice fed a ketogenic diet, in which hepatic TGs increased markedly (36) , and with C57BL/6 mice injected with FGF21, which prevented the development of diet-induced hepatic steatosis (31) . FGF21 induces hepatic expression of Pgc1a, a key transcriptional regulator of energy homeostasis, and causes corresponding increases in FA oxidation (28, 29) . Others have reported that when fed a ketogenic diet, hepatic Pgc1a expression is significantly lower in Fgf21 Ϫ/Ϫ mice (36) . In the current studies, HFD-fed Fgf21 Ϫ/Ϫ mice exhibited reduced hepatic Pgc1a expression compared with HFD-fed WT mice. However, no differences between genotypes were observed in Cpt1a, consistent with previous reports that hepatic Cpt1a mRNA is not regulated in FGF21-treated or FGF21 transgenic mice (16, 27 hanced processing of SREBP-1c to its active nuclear form, which would be anticipated to increase hepatic lipogenesis and likely contributed to increased hepatic lipid accumulation (36) . In the current study, the increased HFD-induced hepatic TG in Fgf21 Ϫ/Ϫ mice was unrelated to FGF21-mediated differences in Srebf1c expression; however, increased formation of nuclear SREBP-1c, through an undefined mechanism, remains a possibility. Of significance, naringenin suppressed Srebf1c expression and hepatic steatosis to a similar extent in HFD-fed WT and Fgf21 Ϫ/Ϫ mice, indicating that this property of naringenin did not require FGF21. HFD-fed Fgf21 Ϫ/Ϫ mice developed significant hyperinsulinemia and glucose intolerance compared with WT controls. For the first time, we show that a HFD in Fgf21 Ϫ/Ϫ mice exacerbates ectopic lipid accumulation in muscle, potentially contributing to impaired glucose tolerance and insulin sensitivity, thereby implicating FGF21 in the regulation of lipid metabolism in muscle and consistent with the concept that FGF21 is a potent sensitizer of insulin action (55) . Despite the marked hyperinsulinemia in HFD-fed Fgf21 Ϫ/Ϫ animals, naringenin treatment completely normalized plasma insulin and improved both insulin and glucose tolerance. In vitro studies in HepG2 hepatocytes show that naringenin is an insulin sensitizer through activation of phosphatidylinositol 3-kinase and MAPK erk signaling pathways, independent of the insulin receptor (6) . Moreover, the significant attenuation of hepatic and muscle TG accumulation, along with reduced adipose tissue, likely contributed to the enhanced insulin sensitivity observed in naringenin-treated Fgf21 Ϫ/Ϫ mice.
These studies demonstrate that naringenin does not require FGF21 to improve metabolic dysregulation in HFDfed mice. However, there are similarities between exogenous FGF21 and naringenin treatment of mice, including the prevention of obesity and hepatic steatosis, and an insulin-sensitizing effect (12, 27, 31, 32) . Furthermore, both FGF21 and naringenin activate MAPK signaling and increase ERK1/2 phosphorylation, in vivo and in vitro, respectively (5, 29) . It is possible that naringenin compensates for FGF21 deficiency by activating similar downstream signaling cascades, leading to increased expression of Pgc1a and Cpt1a.
It is also possible that naringenin mediates its effects through another FGF molecule. FGF21 belongs to the hormone-like subgroup of FGFs that includes FGF19 (FGF15 in mice) and FGF23 (59) . Of interest, FGF19 transgenic mice have decreased adiposity, enhanced insulin sensitivity, and lower plasma glucose, TG, and cholesterol levels (60), similar to FGF21 transgenic animals (34) . Administration of recombinant FGF19 to Lep ob/ob mice decreased body weight, improved glucose tolerance, and prevented hepatic TG accumulation (61) . In the present study, plasma concentrations of FGF15 were not affected by the HFD, naringenin, or genotype, suggesting that the protective effects of naringenin do not involve activation of FGF15 and that FGF15 does not play a compensatory role in the absence of FGF21. However, in Fgf21 Ϫ/Ϫ mice, naringenin increases ␤-Klotho (Klb) expression in the liver, which possibly increases FGF15 activity. Furthermore, even though naringenin does not have a major effect on the expression of FGF21 receptors, Fgfr1 and Fgfr2, in liver or adipose, it is possible that naringenin signals through the primary FGF21 receptor complex (FGFR1/␤-Klotho), independent of FGF21, thereby achieving metabolic protection. Further studies are required to examine this hypothesis.
In conclusion, these studies provide in vivo evidence that in response to a HFD, FGF21 plays a key role regulating adiposity as well as glucose and lipid homeostasis. Furthermore, we show that the flavonoid naringenin can protect against metabolic perturbations induced by highfat feeding in the presence or absence of FGF21. Therefore, naringenin does not require FGF21 to mediate is effects. Nevertheless, these studies raise the possibility that naringenin may share similar signaling pathways with FGF21.
